UBS Group’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-587
| Closed | -$20.2K | – | 10651 |
|
|
2026
Q1 | $20.2K | Buy |
587
+436
| +289% | +$14.9K | ﹤0.01% | 7924 |
|
|
2025
Q4 | $4.97K | Sell |
151
-4,659
| -97% | -$145K | ﹤0.01% | 8745 |
|
|
2025
Q3 | $137K | Buy |
4,810
+814
| +20% | +$22.1K | ﹤0.01% | 6904 |
|
|
2025
Q2 | $102K | Buy |
3,996
+1,090
| +38% | +$27.6K | ﹤0.01% | 7226 |
|
|
2025
Q1 | $79.9K | Buy |
2,906
+1,402
| +93% | +$38.8K | ﹤0.01% | 7220 |
|
|
2024
Q4 | $40.6K | Buy |
+1,504
| New | +$42.2K | ﹤0.01% | 7429 |
|
|
2024
Q3 | – | Sell |
-29
| Closed | -$790 | – | 9690 |
|
|
2024
Q2 | $790 | Buy |
+29
| New | +$777 | ﹤0.01% | 8773 |
|
|
2024
Q1 | – | Sell |
-1,744
| Closed | -$46.4K | – | 9550 |
|
|
2023
Q4 | $46.4K | Buy |
+1,744
| New | +$44K | ﹤0.01% | 6577 |
|
|
2023
Q3 | – | Sell |
-4,261
| Closed | -$112K | – | 9630 |
|
|
2023
Q2 | $112K | Buy |
4,261
+2,500
| +142% | +$66.1K | ﹤0.01% | 5915 |
|
|
2023
Q1 | $46K | Sell |
1,761
-317
| -15% | -$8.5K | ﹤0.01% | 6517 |
|
|
2022
Q4 | $57K | Buy |
2,078
+1,651
| +387% | +$43.9K | ﹤0.01% | 6646 |
|
|
2022
Q3 | $10K | Buy |
+427
| New | +$11K | ﹤0.01% | 8420 |
|
|
2022
Q2 | – | Sell |
-828
| Closed | -$22K | – | 10527 |
|
|
2022
Q1 | $22K | Buy |
828
+464
| +127% | +$12K | ﹤0.01% | 7341 |
|
|
2021
Q4 | $10K | Sell |
364
-594
| -62% | -$15.6K | ﹤0.01% | 8773 |
|
|
2021
Q3 | $25K | Buy |
958
+67
| +8% | +$1.76K | ﹤0.01% | 6916 |
|
|
2021
Q2 | $23K | Sell |
891
-1,373
| -61% | -$35.5K | ﹤0.01% | 7184 |
|
|
2021
Q1 | $58K | Buy |
2,264
+2,253
| +20,482% | +$59.1K | ﹤0.01% | 6396 |
|
|
2020
Q4 | $0 | Buy |
+11
| New | +$274 | ﹤0.01% | 8514 |
|
|
2020
Q1 | – | Sell |
-1,506
| Closed | -$35K | – | 8098 |
|
|
2019
Q4 | $35K | Sell |
1,506
-353
| -19% | -$7.68K | ﹤0.01% | 6559 |
|
|
2019
Q3 | $38K | Buy |
1,859
+265
| +17% | +$5.46K | ﹤0.01% | 6347 |
|
|
2019
Q2 | $34K | Buy |
1,594
+92
| +6% | +$1.91K | ﹤0.01% | 6235 |
|
|
2019
Q1 | $32K | Buy |
+1,502
| New | +$31.2K | ﹤0.01% | 5892 |
|
|
2018
Q3 | – | Sell |
-266
| Closed | -$6K | – | 8079 |
|
|
2018
Q2 | $6K | Buy |
+266
| New | +$5.66K | ﹤0.01% | 7403 |
|
|
2018
Q1 | – | Sell |
-784
| Closed | -$17K | – | 7943 |
|
|
2017
Q4 | $17K | Buy |
+784
| New | +$16.1K | ﹤0.01% | 6672 |
|
|
2017
Q3 | – | Sell |
-1,234
| Closed | -$26K | – | 7817 |
|
|
2017
Q2 | $26K | Sell |
1,234
-66
| -5% | -$1.33K | ﹤0.01% | 6105 |
|
|
2017
Q1 | $26K | Buy |
+1,300
| New | +$25.3K | ﹤0.01% | 5957 |
|
Other funds holding FTXH
OC
MIM
AIP
NP
UBS Group's FTXH Position: Q2 2026 in Review
UBS Group sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q2 2026, closing a stake of 587 shares — an estimated $20.2K sold.
UBS Group first reported a position in FTXH in Q1 2017 and held it in 26 quarters. The position peaked at $137K in Q3 2025. 31 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.
- UBS Group reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 587 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $20.2K.
- UBS Group first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2017 and held it in 26 quarters.
- UBS Group's First Trust Nasdaq Pharmaceuticals ETF position peaked at $137K in Q3 2025.
- 31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.